Eyes Under $1
NextNRG (NASDAQ: NXXT) is gaining visibility after reporting 29% revenue growth and exceeding Wall Street expectations in Q1. The company integrates artificial intelligence (AI) and machine learning (ML) into utility infrastructure, battery storage, renewable energy, wireless EV charging, and mobile fuel delivery through its proprietary Next Utility Operating System®. Its smart microgrid and fleet electrification initiatives continue aligning with growing demand for energy modernization, AI-powered infrastructure, and decarbonization solutions.
Kartoon Studios (NYSE: TOON) continues expanding its intellectual property and streaming ecosystem after securing licensing rights to Mattel (NASDAQ: MAT) brands Masters of the Universe and American Girl for Kartoon Channel!. The company reported Q1 2026 distribution revenue growth of 15% year-over-year, while subscriber engagement surged more than 80% on Kartoon Channel! and over 200% on Ameba. Operating expenses declined 20%, contributing to improved operating performance as TOON advances its transition toward higher-margin IP monetization across streaming, licensing, merchandising, and consumer products.
Virax Biolabs (NASDAQ: VRAX) continues positioning itself within the growing immune diagnostics and Long COVID market, developing T cell-based technologies focused on viral disease detection and immunology profiling. The company’s platform is designed to support the diagnosis and therapeutic monitoring of post-acute infection syndromes, including Long COVID and other chronic immune-related conditions, areas receiving increasing global healthcare attention.
AIM ImmunoTech (NYSE: AIM) is drawing investor interest following a virtual investor presentation highlighting breakthrough data involving Ampligen® for late-stage pancreatic cancer. The company’s lead immunotherapy candidate is being advanced as a potential treatment for one of the world’s most aggressive cancers, while its selective TLR3 agonist platform continues positioning AIM within the expanding immuno-oncology and precision medicine sector.
Sunshine Biopharma (NASDAQ: SBFM) continues expanding its pharmaceutical footprint with 71 marketed generic prescription drugs in Canada and 12 additional launches planned through 2026. The company is also advancing proprietary therapeutic programs, including an mRNA-Lipid Nanoparticle candidate targeting liver cancer and a protease inhibitor focused on SARS-related coronavirus infections, strengthening its exposure to both oncology and antiviral drug development markets.
NextNRG (NASDAQ: NXXT) is gaining visibility after reporting 29% revenue growth and exceeding Wall Street expectations in Q1. The company integrates artificial intelligence (AI) and machine learning (ML) into utility infrastructure, battery storage, renewable energy, wireless EV charging, and mobile fuel delivery through its proprietary Next Utility Operating System®. Its smart microgrid and fleet electrification initiatives continue aligning with growing demand for energy modernization, AI-powered infrastructure, and decarbonization solutions.
Kartoon Studios (NYSE: TOON) continues expanding its intellectual property and streaming ecosystem after securing licensing rights to Mattel (NASDAQ: MAT) brands Masters of the Universe and American Girl for Kartoon Channel!. The company reported Q1 2026 distribution revenue growth of 15% year-over-year, while subscriber engagement surged more than 80% on Kartoon Channel! and over 200% on Ameba. Operating expenses declined 20%, contributing to improved operating performance as TOON advances its transition toward higher-margin IP monetization across streaming, licensing, merchandising, and consumer products.
Virax Biolabs (NASDAQ: VRAX) continues positioning itself within the growing immune diagnostics and Long COVID market, developing T cell-based technologies focused on viral disease detection and immunology profiling. The company’s platform is designed to support the diagnosis and therapeutic monitoring of post-acute infection syndromes, including Long COVID and other chronic immune-related conditions, areas receiving increasing global healthcare attention.
AIM ImmunoTech (NYSE: AIM) is drawing investor interest following a virtual investor presentation highlighting breakthrough data involving Ampligen® for late-stage pancreatic cancer. The company’s lead immunotherapy candidate is being advanced as a potential treatment for one of the world’s most aggressive cancers, while its selective TLR3 agonist platform continues positioning AIM within the expanding immuno-oncology and precision medicine sector.
Sunshine Biopharma (NASDAQ: SBFM) continues expanding its pharmaceutical footprint with 71 marketed generic prescription drugs in Canada and 12 additional launches planned through 2026. The company is also advancing proprietary therapeutic programs, including an mRNA-Lipid Nanoparticle candidate targeting liver cancer and a protease inhibitor focused on SARS-related coronavirus infections, strengthening its exposure to both oncology and antiviral drug development markets.
